INTS (Intensity Therapeutics) Short-Term Debt & Capital Lease Obligation : $0.03 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Intensity Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.03 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Intensity Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.10 Mil.

Intensity Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Intensity Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics Short-Term Debt & Capital Lease Obligation Chart

Intensity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.17

2.20

4.49

0.02

0.03

Intensity Therapeutics Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial														0.03	0.03	0.03	0.03	0.03

Intensity Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Intensity Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Intensity Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779

Website

https://www.intensitytherapeutics.com

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Executives

Emer Leahy	director	1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers	officer: Executive VP of CF	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender	director, 10 percent owner, officer: President and CEO	765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg	director	PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski	officer: Interim CFO	61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880